Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00364351 · ClinicalTrials.gov registry record · Phase 3
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase 3 study, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,574
- Enrollment target
NCT00364351 is a Phase 3 study that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 1,574 participants.
The verdict
NCT00364351, a Phase 3 study, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,574 participants
- Enrollment target
Study Summary
To determine if ZD6474 a new investigational drug, is effective in treating Non Small Lung Cancer and if so, how it compares with another type of anti cancer therapy chemotherapy, Erlotinib
Interventions
- DRUG Erlotinib
- DRUG Vandetanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,574 participants |
| Start Date | 2006-08 |
| Est. Completion | 2016-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00364351
The ClinicalTrials.gov registry entry for NCT00364351 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,574 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Erlotinib is the first listed.
NCT00364351 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00364351 about?
NCT00364351 is a clinical study titled "Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy". To determine if ZD6474 a new investigational drug, is effective in treating Non Small Lung Cancer and if so, how it compares with another type of anti cancer therapy chemotherapy, Erlotinib
What is the current status of trial NCT00364351?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,574 participants. The study started on 2006-08. Estimated completion is 2016-11.
What interventions are being tested in trial NCT00364351?
The interventions under investigation include: Erlotinib (DRUG), Vandetanib (DRUG).
Who is sponsoring clinical trial NCT00364351?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.